MetLife Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

MetLife Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$148K	Sell	1,162 -194	-14%	-$24.2K	﹤0.01%	2360
2025 Q4	$165K	Sell	1,356 -175	-11%	-$20.1K	﹤0.01%	2364
2025 Q3	$153K	Sell	1,531 -640	-29%	-$57.6K	﹤0.01%	2460
2025 Q2	$180K	Buy	2,171 +246	+13%	+$19.6K	﹤0.01%	2248
2025 Q1	$156K	Buy	+1,925	New	+$172K	﹤0.01%	2324

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MetLife Investment Management's XBI Position: Q1 2026 in Review

MetLife Investment Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 14% in Q1 2026, selling an estimated $24.2K and leaving 1,162 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #2360.

MetLife Investment Management first reported a position in XBI in Q1 2025 and has held it in 5 quarters since. The position peaked at $180K in Q2 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

MetLife Investment Management held 1,162 shares of State Street SPDR S&P Biotech ETF worth $148K as of Q1 2026.
MetLife Investment Management sold 194 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $24.2K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2360 holding.
MetLife Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2025 and has held it in 5 quarters since.
MetLife Investment Management's State Street SPDR S&P Biotech ETF position peaked at $180K in Q2 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.